Method for purifying pluripotent stem cells by using equilibrium salt buffer solution without calcium ions and magnesium ions
By treating pluripotent stem cells with a balanced salt solution free of calcium and magnesium ions, the problems of cell damage, cumbersome procedures, and high costs in the purification process of pluripotent stem cells in the prior art are solved, and efficient and low-damage purification of pluripotent stem cells is achieved.
Patent Information
- Application Number
- CN202411159598.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-08
AI Technical Summary
Existing technologies for pluripotent stem cell purification suffer from risks of cell damage, cumbersome procedures, long processing times, and high costs. In particular, it is difficult to efficiently and with minimal damage separate and purify pluripotent stem cells in spontaneous differentiation systems of PSCs.
Pluripotent stem cells are treated with a balanced salt solution (such as DPBS) that does not contain calcium and magnesium ions. This process achieves efficient purification through soaking and gentle pipetting, simplifying the operation and reducing costs.
It achieves efficient purification of pluripotent stem cells, reduces the risk of cell damage, simplifies the operation steps, lowers costs, and the purification time is no more than 1 hour.
Smart Images

Figure CN118909930A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to a method for purifying pluripotent stem cells by using a balanced salt buffer solution free of calcium ions and magnesium ions. Background Art
[0002] Tissue engineering and cell therapy based on differentiated cells from pluripotent stem cells (PSCs) is a promising treatment method and has been applied in clinical and preclinical studies of various diseases including diabetes, acute stroke, macular degeneration, ischemic cardiomyopathy, etc. Maintaining the undifferentiated state of PSCs as the starting point of differentiation is crucial for the differentiation and subsequent treatment of PSC-derived cells. However, changes in the external environment (e.g., temperature, CO2 concentration, oxygen concentration during culture and operation), abnormal culture medium components (due to the presence of a large number of small molecules or recombinant proteins in the pluripotent stem cell culture medium, the titer may decay over time and temperature), and cell manipulation (e.g., viral transfection) lead to abnormal differentiation of PSCs during the expansion period.
[0003] Directly discarding PSCs with differentiated cells often puts researchers under pressure from both cost and time waste. Because PSCs cell lines, especially brand new PSCs constructed by transfection viruses, are often precious and have batch effects. In addition, with the rapid progress of basic research and clinical practice of PSCs-derived cells, PSCs obtained based on the reprogramming of patients' own cells are becoming more and more a hot spot for research and application, because cells derived from patients themselves are basically non-immunogenic to the patients themselves. But this also means that it is impossible to amplify all patient-derived PSCs on a large scale during the operation, because such an operation is not only labor-intensive but also cost-effective. For these reasons, the spontaneous differentiation of PSCs during the expansion period is still a huge obstacle in the basic research and clinical application of PSCs. Developing a harmless operation method for separating PSCs from the spontaneous differentiation system of PSCs has extremely strong practical and clinical application significance.
[0004] At present, a variety of schemes have been applied to the purification of PSCs, such as flow sorting, magnetic bead sorting, gene editing, and single cloning. Among them, the flow sorting method is based on flow sorting technology and the extremely high stemness level of PSCs for purification. Taking the SSEA-4 marker as an example, SSEA-4 is highly expressed in PSCs but not expressed in differentiated cells and normal cells of the body. By marking SSEA-4 in PSCs and using flow cytometry for cell sorting, PSCs can be sorted out from differentiated cells in the PSC self-differentiation system. The magnetic bead sorting method uses Miltenyi Biotec's commercially available magnetic beads labeled with antibodies to recognize iPSCs-specific markers, and the antibody-labeled iPSCs are separated and purified from mixed cells by magnetic adsorption (Rapid and Highly Efficient Isolation and Purification of Human Induced Pluripotent Stem Cells; A Rapid and Highly Efficient Method for the Isolation, Purification, and Passaging of Human-Induced Pluripotent Stem Cells). Gene editing methods mainly include: when the miRNA target sequence and additional sequences are inserted downstream of the poly(A) tail, mRNA translation is inhibited. However, in the presence of the target miRNA, the translation inhibitory sequence after the poly(A) tail is removed by miRNA-mediated targeted cleavage, generating translationally active mRNA in a cell type-specific manner. Therefore, mRNA acts as a miRNA-ON switch, and this method is used to strictly eliminate non-target cells, thereby enhancing the robustness and versatility of the cell purification system (A versatile and robust cell purification system with an RNA-only circuit composed of microRNA-responsive ON and OFF switches). The single cloning method is a method of obtaining purified PSCs by plating cells at very low density to form different monoclonal cell clusters, and then performing single cloning operations on the PSCs to continue culturing.
[0005] However, the above methods all have certain defects: (1) Potential damage risk: gene editing methods, flow sorting, and magnetic bead sorting methods may cause potential damage to differentiated cells during the processing process; gene editing methods may also cause potential gene mutations in target cells and immune responses caused by the introduction of plasmids / viruses; (2) cumbersome steps: gene editing methods involve the design, synthesis, transfection, and positive cell screening of transfection plasmids, which consumes huge manpower and material costs in the preparation stage and increases the risk of failure due to cumbersome steps; (3) time-consuming: the cell preparation stage of gene editing methods takes a long time. Starting from plasmid design, the construction time of cell lines often exceeds 2 weeks. Genetic modification methods, small molecule treatment methods, and physical treatment methods often need to induce cell apoptosis or other forms of cell death during the iPSCs clearance stage, which often takes hours or even days. The monoclonal picking method requires the steps of monoclonal selection, monoclonal formation, and monoclonal expansion, which takes a long time and requires high operator proficiency. (4) High cost: The above methods require increased investment in reagents and expenses during the PSCs clearance process, which increases costs. Summary of the invention
[0006] In view of this, in order to overcome the deficiencies in the prior art, the present invention aims to provide a method for purifying pluripotent stem cells using a balanced salt buffer solution that does not contain calcium ions and magnesium ions.
[0007] The present invention aims to purify abnormally differentiated PSCs or PSCs co-cultured with other cells using DPBS (Ca-Mg-), a method with low risk of cell damage, simple steps, short time and low cost, to solve the common problem of abnormal differentiation in the PSC culture process, and provide a new operating method for the increasingly "hot" research on signal crosstalk between PSCs and PSC-derived cells.
[0008] The above-mentioned object of the present invention is achieved through the following technical solutions:
[0009] A first aspect of the present invention provides use of a balanced salt solution free of calcium ions and magnesium ions in purifying pluripotent stem cells.
[0010] Further, the balanced salt solution includes DPBS, EBSS, HBSS, PBS, GBSS, RBSS, SBSS, TBS and / or TBSS;
[0011] Optionally, the balanced salt solution is DPBS.
[0012] Further, the pluripotent stem cells include iPSC, ESC and / or EPSC;
[0013] Optionally, the pluripotent stem cells are iPSCs.
[0014] In the present invention, the balanced salt solution (BSS) refers to a salt solution in which the electrolyte content in the solution is similar to that in the plasma. The balanced salt solution is mainly composed of inorganic salts and glucose, which is consistent with the environmental conditions such as pH value and osmotic pressure under the cell growth state, and has the functions of maintaining osmotic pressure, controlling acid-base balance, and supplying energy and inorganic salt components necessary for cell survival and metabolism. It also plays an important role in maintaining osmotic pressure, buffering and adjusting solution pH.
[0015] In some embodiments, the balanced salt solution free of calcium ions and magnesium ions includes, but is not limited to: Dulbecco's phosphate buffered saline (DPBS) free of calcium ions and magnesium ions, Earle's balanced salt solution (EBSS), Hanks' balanced salt solution (HBSS), phosphate buffered saline (PBS), Gey's balanced salt solution (GBSS), Ringer's balanced salt solution (RBSS), Simm's balanced salt solution (SBSS), TRIS buffer (TBS), Tyrode's balanced salt solution (TBSS), Alsever's solution, Puck's balanced salt solution, physiological saline and / or Ringer's solution. Any balanced salt solution free of calcium ions and magnesium ions known in the art is within the scope of protection of the present invention.
[0016] In the present invention, the pluripotent stem cells (PSCs) are a type of multipotent cells with the ability of self-renewal and self-replication. Under certain conditions, it can differentiate into a variety of APSC pluripotent cells. Pluripotent stem cells have the potential to differentiate into a variety of cell tissues, but have lost the ability to develop into a complete individual, and their developmental potential is subject to certain restrictions.
[0017] In some embodiments, the pluripotent stem cells include but are not limited to induced pluripotent stem cells (iPSC), embryonic stem cells (ESC), expanded pluripotent stem cells (EPSC), mesenchymal stem cells (MSC) and / or parthenogenetic stem cells (PSC). Any pluripotent stem cells known in the art are within the scope of protection of the present invention.
[0018] In a specific embodiment of the present invention, the present invention applies a balanced salt solution (DPBS (Ca-Mg-)) without calcium ions and magnesium ions for the first time to the efficient purification of pluripotent stem cells. The purpose of efficiently purifying pluripotent stem cells can be achieved by only using a balanced salt solution (DPBS (Ca-Mg-)) without calcium ions and magnesium ions that is commonly used in cell culture and has low damage to cells to treat a cell system in which pluripotent stem cells are abnormally differentiated or a cell system in which pluripotent stem cells are co-cultured with other cells. The method provided by the present invention can not only minimize the potential risk of cell damage, but also has the advantages of simple operation (only a balanced salt solution without calcium ions and magnesium ions is needed for soaking), short time consumption (the whole purification process does not exceed 1 hour), and low cost.
[0019] A second aspect of the present invention provides a method for purifying pluripotent stem cells.
[0020] Furthermore, the method comprises the following step: treating the mixed cell system containing pluripotent stem cells in need with a balanced salt solution free of calcium ions and magnesium ions to purify the pluripotent stem cells.
[0021] Further, the balanced salt solution includes DPBS, EBSS, HBSS, PBS, GBSS, RBSS, SBSS, TBS and / or TBSS;
[0022] Optionally, the balanced salt solution is DPBS;
[0023] Optionally, the pluripotent stem cells include iPSCs, ESCs and / or EPSCs;
[0024] Optionally, the pluripotent stem cells are iPSCs.
[0025] Furthermore, the mixed cell system also includes cells that are not pluripotent stem cells;
[0026] Optionally, the non-pluripotent stem cell cells include cells derived from pluripotent stem cells;
[0027] Optionally, the pluripotent stem cell-derived cells include pluripotent stem cell-derived MSCs, pluripotent stem cell-derived osteoblasts, pluripotent stem cell-derived fibrochondrocytes and / or pluripotent stem cell-derived EPCs.
[0028] In some embodiments, the cells derived from pluripotent stem cells refer to cells obtained by abnormal differentiation of pluripotent stem cells, including but not limited to: induced pluripotent stem cell-derived mesenchymal stem cells (iMSC), induced pluripotent stem cell-derived osteoblasts (iOB), induced pluripotent stem cell-derived chondrocytes (iFC) and / or induced pluripotent stem cell-derived endothelial progenitor cells (iEPC).
[0029] Further, the method comprises the following steps:
[0030] (1) treating a mixed cell containing pluripotent stem cells in need with a balanced salt solution free of calcium ions and magnesium ions to obtain a supernatant solution;
[0031] (2) After the supernatant solution is centrifuged, the supernatant is discarded to obtain purified pluripotent stem cells.
[0032] Further, the treatment condition is 37°C for 30 min;
[0033] Optionally, the amount of the balanced salt solution without calcium ions and magnesium ions is 0.5-3.5 mL per well of the cell culture plate;
[0034] Optionally, the amount of the balanced salt solution without calcium ions and magnesium ions is 3 mL per well of the cell culture plate.
[0035] Furthermore, step (1) further comprises the following step: using a pipette to gently blow the cells treated with a balanced salt solution free of calcium ions and magnesium ions.
[0036] Furthermore, after the mixed cells containing pluripotent stem cells described in step (1) are treated with a balanced salt solution without calcium ions and magnesium ions, the edges of the cells (pluripotent stem cells) growing in a clone-like manner are shiny, and the cell adhesion is rapidly lost, while the morphology of other cells (cells other than pluripotent stem cells) in the mixed cells does not change significantly. After gently blowing, the pluripotent stem cells are completely out of contact with the culture dish, while the other cells (cells other than pluripotent stem cells) in the mixed cells remain in an adherent state.
[0037] In a specific embodiment of the present invention, the present invention verifies the pluripotent stem cells purified by the above method, and the experimental results show that the pluripotent stem cells purified by the above method grow in a clonal manner, the cell morphology is close to iPSCs, and most of the purified cells express the pluripotent stem cell protein markers OCT4, SOX2, and Nanog, indicating that the method provided by the present invention has a high purification efficiency for purifying pluripotent stem cells.
[0038] In addition, the experimental results show that the pluripotent stem cells purified by the above method have the ability to form embryoid bodies (EBs) and differentiate into three germ layer cells in vitro, which is consistent with iPSCs, indicating that the method provided by the present invention has a high purification efficiency for purifying pluripotent stem cells.
[0039] In the present invention, the non-pluripotent stem cell cells refer to cells other than pluripotent stem cells. For example, the non-pluripotent stem cell cells include, but are not limited to, adult stem cells and differentiated cells. In some embodiments, the non-pluripotent stem cell cells include cells abnormally differentiated from pluripotent stem cells or other cells.
[0040] In the present invention, the mixed cell system containing pluripotent stem cells can be cultured in a manner selected according to the actual experimental needs of technicians in this field. For example, a cell culture plate, a cell culture dish or a cell culture flask can be selected to culture the above-mentioned mixed cells. The present invention has no special restrictions on the cell culture container, and any culture container that can be used to culture the mixed cells is within the protection scope of the present invention.
[0041] In some embodiments, the cell culture container can be divided into glass and plastic according to the material. Among them, the advantage of glass material is that it is easy to grow cells and clean, and can be used repeatedly. The advantage of plastic is that it is cheap, disposable, and reduces the risk of contamination. At present, the most commonly used plastic in the laboratory is polystyrene (PS). The low cost of PS and its inert chemical properties make it the best choice for disposable culture surfaces.
[0042] In some embodiments, there are three common cell culture vessels, namely: culture flasks, culture dishes, and multi-well culture plates.
[0043] The culture dish is shallow and easy to operate. It is often used for cell growth and reproduction. There are many sizes of culture dishes (single hole or multi-hole) to choose from. They are named according to the diameter of the bottom surface. The commonly used sizes are 6cm and 10cm. Compared with culture bottles, it is easier to select single cell colonies from culture dishes and the operation is more convenient. However, due to the larger opening, the risk of contamination is also correspondingly higher.
[0044] Culture bottles are named by their surface area, such as T25, T75, T175, the number represents the bottom area of the bottle, T25 is 25cm 2 . The bottle body design can be divided into straight neck or curved neck. Curved neck culture bottles are easier to operate. Using a pipette or a long gun tip can touch the bottom surface, and it can prevent the bottle cap from contacting the culture medium, reducing liquid splashing and reducing the risk of contamination. According to different cell requirements, the bottle cap design can be divided into two types: filter membrane and seal. For cells that require CO2 ventilation under culture conditions, it is recommended to use a breathable filter membrane model.
[0045] Multi-well culture plates are also commonly made of plastic and are used in various detection experiments, such as cell cloning, scratch, and cytotoxicity experiments. Commonly used culture plates are divided into 6-well, 12-well, 24-well, and 96-well plates according to the number of holes.
[0046] The third aspect of the present invention provides the application of any of the following aspects:
[0047] (1) Use of a balanced salt solution free of calcium ions and magnesium ions in purifying pluripotent stem cells from abnormally differentiated pluripotent stem cells;
[0048] (2) Use of a balanced salt solution free of calcium ions and magnesium ions for purifying pluripotent stem cells from pluripotent stem cells co-cultured with non-pluripotent stem cells;
[0049] (3) Application of balanced salt solution without calcium ions and magnesium ions in the study of signal crosstalk between pluripotent stem cells and pluripotent stem cell-derived cells.
[0050] Further, the balanced salt solution includes DPBS, EBSS, HBSS, PBS, GBSS, RBSS, SBSS, TBS and / or TBSS;
[0051] Optionally, the balanced salt solution is DPBS;
[0052] Optionally, the pluripotent stem cells include iPSCs, ESCs and / or EPSCs;
[0053] Optionally, the pluripotent stem cells are iPSCs.
[0054] In some embodiments, the abnormally differentiated pluripotent stem cell culture system comprises pluripotent stem cells and other cells derived from pluripotent stem cells, and the other cells include but are not limited to: mesenchymal stem cells derived from pluripotent stem cells, osteoblasts derived from pluripotent stem cells, fibrochondrocytes derived from pluripotent stem cells, endothelial progenitor cells derived from pluripotent stem cells, etc.
[0055] Compared with the prior art, the present invention has the following beneficial effects:
[0056] The present invention applies a balanced salt solution (DPBS (Ca-Mg-)) free of calcium ions and magnesium ions to the purification of pluripotent stem cells for the first time. Based on this, the present invention develops a pluripotent stem cell purification scheme with high purification efficiency, no harm to cells, and extremely high cost performance. The purification scheme purifies pluripotent stem cells only through physical changes, which is completely inconsistent with the methods disclosed in the prior art. The pluripotent stem cell purification scheme provided by the present invention can achieve efficient purification of pluripotent stem cells by only using a balanced salt solution (DPBS (Ca-Mg-)) free of calcium ions and magnesium ions commonly used in the cell culture process and low in cell damage after abnormal differentiation of PSCs or co-culture with other cells, which minimizes the potential risk of cell damage and is significantly superior to the conventional pluripotent stem cell purification methods disclosed in the prior art, specifically as follows:
[0057] (1) Compared with the methods disclosed in the prior art, the method for purifying pluripotent stem cells provided by the present invention is simple to operate and only requires soaking in DPBS (Ca-Mg-);
[0058] (2) Compared with the methods disclosed in the prior art, the method for purifying pluripotent stem cells provided by the present invention is time-saving, and the entire purification process does not exceed 1 hour;
[0059] (3) Compared with the methods disclosed in the prior art, the method for purifying pluripotent stem cells provided by the present invention is low in cost and only uses DPBS (Ca-Mg-) with relatively low cost (for example, only 3 mL of DPBS (Ca-Mg-) is needed to purify PSCs in each well of a 6-well plate, and the calculated price of 500 mL of balanced salt solution is about RMB 100, so only RMB 0.6 is needed to remove PSCs in each well of a 6-well plate). BRIEF DESCRIPTION OF THE DRAWINGS
[0060] Figure 1 Results of evaluating the ability of iPSCs and other differentiated cells to respond to DPBS (Ca-Mg-), including: Figure A: light microscopic results of iPSCs, iFCs, iOBs, iMSCs, and Fibroblasts treated with a balanced salt solution without calcium and magnesium; Figure B: crystal violet staining results of iPSCs, iFCs, iOBs, iMSCs, and Fibroblasts treated with a balanced salt solution without calcium and magnesium; Figure C: immunofluorescence staining results of stemness genes OCT4, SOX2, and NANOG in iPSCs, iOBs, and iFCs used in subsequent experiments; Figure D: flow cytometry analysis results of stemness genes OCT4 and SOX2 in iOBs and iFCs used in subsequent experiments;
[0061] Figure 2The results of the co-culture system of iPSCs and differentiated cells are shown in Figure A. The light microscopic results of the establishment of the co-culture system of iPSCs, iFCs and iOBs, the treatment with a balanced salt solution without calcium and magnesium ions, and the continued culture of iPSCs (P1, P2 and P3) purified with a balanced salt solution without calcium and magnesium ions; Figure B: The immunofluorescence staining results of the stemness genes OCT4, SOX2 and NANOG in the co-culture system of iPSCs, iFCs and iOBs; Figure C: The immunofluorescence staining results of the stemness genes OCT4, SOX2 and NANOG in iPSCs (P1, P3 and P5) purified with a balanced salt solution without calcium and magnesium ions; Figure D: The flow cytometry analysis results of the stemness genes OCT4 and SOX2 in iPSCs and iPSCs (P3) purified with a balanced salt solution without calcium and magnesium ions;
[0062] Figure 3 The purification effect of DPBS (Ca-Mg-) on the co-culture system (iOB+iPSC, iFC+iPSC), wherein, Figure A: principal component analysis results of genes of iPSCs, iPSC / iFC, iPSCs / iOB, and fibroblasts; Figure B: Venn diagram of differential genes among iPSCs, iPSC / iFC, iPSCs / iOB, and fibroblasts; Figure C: volcano diagram of differential genes among iPSCs, iPSC / iFC, iPSCs / iOB, and fibroblasts; Figure D: cluster diagram of differential genes among iPSCs, iPSC / iFC, iPSCs / iOB, and fibroblasts; Figure E: heat map of differential genes among iPSCs, iPSC / iFC, iPSCs / iOB, and fibroblasts;
[0063] Figure 4 The results of the identification of the EB formation ability of iPSC / iOB and iPSC / iFC, where A shows the optical microscopic morphology of EB balls at different time points, B shows the gene expression of iPSC / iFC and iPSCs / iOB after forming EB balls, and C shows the immunofluorescence staining results of the three germ layer differentiation markers of EB balls formed by iPSC / iFC and iPSCs / iOB after they adhere to the wall;
[0064] Figure 5The results of the identification of the in vitro three-germ layer differentiation ability of iPSC / iOB and iPSC / iFC, including: Figure A: light microscopic morphology of differentiated neuroectoderm cells, fibrochondrocytes and mesendoderm cells; Figure B: immunofluorescence staining results of the three-germ layer differentiation markers after EB spheres formed by iPSC / iFC and iPSCs / iOB adhere to the wall; Figure C: gene expression of iPSC / iFC and iPSCs / iOB after EB spheres are formed; Figure D: expression of ectoderm markers, fibrochondrocyte markers, endoderm markers and pluripotent stem cell markers after iPSC / iFC and iPSC / iOB are directed to differentiate into neuroectoderm, fibrochondrocytes and endoderm. DETAILED DESCRIPTION
[0065] The present invention is further described below in conjunction with specific embodiments, which are only used to explain the present invention and cannot be understood as limiting the present invention. It can be understood by those skilled in the art that various changes, modifications, substitutions and variations can be made to these embodiments without departing from the principles and purpose of the present invention, and the scope of the present invention is defined by the claims and their equivalents.
[0066] The reagents and raw materials used in the present invention are easily obtained by ordinary technicians in the field and can be obtained from commercial channels unless otherwise specified. The experimental methods in the present invention that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. In particular, the following examples are only used to illustrate the present invention and should not limit the scope of the present invention in any way.
[0067] Example 1 Process of differentiation from iPSCs to mesenchymal stem cells (iMSCs), osteoblasts (iOBs), and fibrochondrocytes (iFCs)
[0068] 1. iMSCs: PSCs were induced to differentiate into iMSCs using the method described in Chinese patent publication CN115094031A.
[0069] 2. iOBs: PSCs were induced to differentiate into iOBs using the method described in Chinese Patent Publication CN117535234A.
[0070] 3. iFCs: PSCs were induced to differentiate into iFCs using the method described in Chinese patent publication CN117126801A.
[0071] Example 2 iPSCs and other differentiated cells have inconsistent abilities to respond to DPBS (Ca-Mg-)
[0072] 1. Experimental methods
[0073] iPSCs, iFCs, iOBs, iMSCs, and fibroblasts were plated in 6-well plates coated with Matrigel. To verify the responsiveness of different cells to DPBS (Ca-Mg-) treatment, the five types of cells were treated with DPBS (Ca-Mg-) for 30 minutes at 37°C, and the changes in cell morphology / clonal morphology of different cells were observed. To compare the differences in the adhesion ability of the five cells after DPBS (Ca-Mg-) treatment, the cells treated with DPBS (Ca-Mg-) were gently blown with a pipette, and then the supernatant was discarded. 4% paraformaldehyde was fixed at room temperature for 10 minutes, and crystal violet solution was used to treat at room temperature for 15 minutes before taking photos and recording. In subsequent experiments, the present invention uses iOBs and iFCs to simulate abnormally differentiated cells or co-cultured cells. Immunofluorescence technology and flow cytometry were used to detect the pluripotent stem cell markers OCT4, SOX2, and Nanog of the three groups of cells of iPSCs, iOBs, and iFCs, and these markers were used for subsequent experiments to evaluate the feasibility of purification efficiency.
[0074] 2. Experimental results
[0075] like Figure 1 As shown in A, after PSCs were treated with DPBS (Ca-Mg-) for 30 minutes (37°C), the PSCs clones glowed, the individual cells shrank and became round, and the cell adhesion was lost rapidly. However, the cell morphology of other cells (iFCs, iOBs, iMSCs, and fibroblasts) did not change significantly. After gently blowing, PSCs completely broke away from the culture dish, while other cells (iFCs, iOBs, iMSCs, and fibroblasts) remained attached to the wall, which was further confirmed by the crystal violet staining results ( Figure 1 B). Subsequently, we used PSCs cell line (iPSCs-001-5, prepared by the method described in Chinese patent publication CN109913494A) and two iPSCs-derived differentiated cells (iFCs and iOBs) for subsequent experiments. Immunofluorescence results showed that iPSCs expressed high levels of pluripotent stem cell protein markers OCT4, SOX2 and Nanog, while the same marker proteins were expressed at low levels in differentiated cells (iFCs and iOBs). Figure 1 C). Flow cytometry analysis also showed that only a very small number of iFCs and iOBs were positive for OCT4 (iFCs: 0.84%; iOBs: 0.44%) and SOX2 (iFCs: 0.12%; iOBs: 0.16%). These results indicate that the stemness genes OCT4 and SOX2 can be used as effective markers to identify iPSCs and differentiated cells (iFCs and iOBs).
[0076] Example 3 Construction of iPSCs and differentiated cell co-culture system
[0077] 1. Experimental methods
[0078] In order to simulate the abnormal differentiation of iPSCs during culture and the co-culture experiment with other cells, the present invention constructed a co-culture system of iPSCs and iPSC-derived cells (iFCs and iOBs). Specifically, PSCs were first plated in a Matrigel-coated 6-well plate (500,000 cells / well), and the plating medium (2 mL per well) was selected to be E8 medium + 10 μM Y27632 (HY-10071, MedChemExpree, USA) and cultured at 37°C. After 4 hours of plating, the culture medium was replaced with E8 medium and cultured at 37°C for 20 hours. 24 hours after the plating, discard the culture medium and add a suspension of differentiated cells (iFC and iOB) containing differentiated cell culture medium (iOB and iFC, 2 mL per well), 500,000 cells per well, wherein the differentiated cells iOB adopt the method described in Chinese patent publication CN117535234A, and the differentiated cells iFC adopt the method described in Chinese patent publication CN117126801A. Continue to culture at 37°C for 8 hours. The co-culture system of PSCs and iOBs is subsequently labeled as iOB+iPSC, and the co-culture system of PSCs and iFCs is subsequently labeled as iFC+iPSC. The co-cultured cells were recorded by light microscopy, and the expression of pluripotent stem cell protein markers of co-cultured cells was detected by immunofluorescence.
[0079] 2. Experimental results
[0080] like Figure 2 As shown in A, iPSCs and differentiated cells (iOB and iFC) successfully adhered to the wall, iPSCs grew in a clonal morphology, and differentiated cells (iOB and iFC) were scattered between the clones. Immunofluorescence results showed that the cells growing in a clonal manner expressed pluripotent stem cell protein markers OCT4, SOX2, and Nanog, and the cell morphology was basically consistent with that of iPSCs; the scattered cells around did not express pluripotent stem cell protein markers OCT4, SOX2, and Nanog, and the cell morphology was similar to that of differentiated cells (iOB and iFC) ( Figure 2 B). The above results indicate the successful construction of the co-culture system of iPSCs and differentiated cells (iOBs and iGCs).
[0081] Example 4 Verification of the Purification Ability of DPBS (Ca-Mg-) for iPSCs in the Co-culture System of iPSCs and Differentiated Cells
[0082] 1. Experimental Materials
[0083] E8 medium TeSR TM -E8 TMY27632 was purchased from MedChemExpree (USA) with the catalog number HY-10071.
[0084] 2. Experimental methods
[0085] The cells of the co-culture system (iFC+iPSC, iOB+iPSC) were treated with DPBS (Ca-Mg-) at 37°C for 30 minutes. The amount of DPBS (Ca-Mg-) was as follows: 2 mL of DPBS (Ca-Mg-) was added to each well of the culture plate, the cells were blown gently, the supernatant was centrifuged, the supernatant was discarded, E8+10 μM Y27632 was resuspended, and the cells were plated in a 6-well plate coated with Matrigel, and marked as P1. When the cell confluence reached 80%, they were passaged and marked as P2, and then passaged in sequence. The purified cells of P1, P3, and P5 were observed by light microscopy, and the expression of pluripotent stem cell protein markers OCT4, SOX2, and Nanog in different groups of cells was detected by immunofluorescence. Flow cytometry was used to detect the positive rates of pluripotent stem cell protein markers OCT4 and SOX2 in purified iPSCs (P3) and original iPSCs. iPSCs co-cultured with iFCs and purified were labeled as iPSC / iFCs, and iPSCs co-cultured with iOBs and purified were labeled as iPSC / iOBs.
[0086] Subsequently, RNA-Seq was used to detect iPSCs, iPSC / iFCs (P5), iPSC / iOBs (P5) and fibroblasts (as a negative control) to verify the purification efficiency of DPBS (Ca-Mg-) for iPSCs.
[0087] Subsequently, the pluripotency of iPSC / iFC(P5) and iPSC / iOB(P5) was verified by forming embryoid bodies (EBs) and three-germ layer differentiation experiments.
[0088] EBs formation protocol: The EB formation medium is as follows: DMEM / F12, 2mM GlutaMAX, 20% KSR, 0.1mMNEAA, 0.1mM 2-mercaptoethanol. EB differentiation was performed using the protocol recommended by Thermo Fisher Scientific. In brief, the digested cells were plated into low-adhesion 6-well plates using EB formation medium + 10μM Y27632, and the medium was replaced with EB formation medium after 24h, and the medium was changed every other day. After 12 days of EB culture, the formed EBs were transferred to Matrigel-coated 6-well plates using EB formation medium, and cultured for another 2 days, then the medium was discarded and fixed with 4% paraformaldehyde. qPCR was used to detect the gene expression of the three germ layer differentiation markers and pluripotent stem cell markers SOX17, Brachyury, DLX3, PAX6, OCT4, and SOX2. Immunofluorescence was used to detect the differentiation markers of the three germ layers: β-Tublin, Nestin, αSMA, PDGFRa, and GATA4.
[0089] Three-germ layer differentiation scheme: Different cells were differentiated into neuroectoderm, fibrochondrocytes (FC) and endoderm according to different differentiation schemes. The expression of differentiation markers of each germ layer was detected by qPCR and immunofluorescence.
[0090] Neuroectodermal differentiation protocol: Neuroectodermal differentiation medium is as follows: DMEM / F12, 1X B-27, 1X N-2, 1X MEM NEAA, 1X GlutaMAX, 25μg / mL INS, 10μM SB431542, 100nM LDN193189, 100nM RA, 55μM β-mercaptoethanol, use E8 medium + 10μM Y27632 to plate cells in Matrigel-coated 6-well plates, with a plating density of 20,000 / cm2. On the second day, replace the neuroectodermal differentiation medium, and change the medium every day for 7 days.
[0091] FC differentiation protocol: The method described in Chinese patent publication CN117126801A was used.
[0092] Endoderm differentiation protocol: Endoderm differentiation medium was as follows: IMDM / F12, 0.5% BSA, 550nM thioglycerol, 1% CDLC, 1% P / S, 100ng / mL Activin A, 3μM Chir99021. In brief, cells were plated in Matrigel-coated 6-well plates using E8 medium + 10μMY27632, and E8 medium was replaced after 4 hours. After the cell confluence reached 70%, the endoderm differentiation medium was replaced, and the medium was changed daily for 5 days.
[0093] 3. Experimental results
[0094] like Figure 2 As shown in A, in the co-culture system (iOB+iPSC, iFC+iPSC), after being treated with DPBS (Ca-Mg-) at 37°C for 30 minutes, the edges of cells growing in a clone-like manner glowed, and cell adhesion was rapidly lost. Some of them were completely out of contact with the culture dish after being gently blown. The culture dish supernatant (including DPBS (Ca-Mg-) and detached cells) was centrifuged, the supernatant was discarded, and the precipitated cells were plated on a Matrigel-coated 6-well plate using E8 medium + 10μM Y27632. P1, P3 and P5 purified cells (iPSC / iFC, iPSC / iOB) were observed to grow in a clone-like manner, and the cell morphology was close to that of iPSCs ( Figure 2 A). The purified cells (iPSC / iFC, iPSC / iOB) were subjected to immunofluorescence staining. The results showed that most of the purified cells (iPSC / iFC, iPSC / iOB) expressed pluripotent stem cell protein markers OCT4, SOX2, Nanog ( Figure 2 C). The purified iPSCs were positive for OCT4 (iPSC / iFC: 99.19%; iPSC / iOB: 98.62%) and SOX2 (iPSC / iFC: 98.52%; iPSC / iOB: 98.31%). This verified the purification efficiency of DPBS (Ca-Mg-) for the co-culture system (iOB+iPSC, iFC+iPSC) from the protein expression level.
[0095] Subsequently, the present invention detected the purification effect of DPBS (Ca-Mg-) on the co-culture system (iOB+iPSC, iFC+iPSC) by transcriptome sequencing. Untreated iPSCs were used as the positive control group, and Fibroblasts were used as the negative control group to detect the gene expression of iPSC / iFC and iPSC / iOB. The results of principal component analysis are shown in Figure 2. Figure 3 As shown in A, the main components of gene expression of iPSCs, iPSC / iFC and iPSC / iOB are closer and located on the left side of the coordinate axis; Fibroblast is different from other cells and is located on the right side of the coordinate axis. The parameters |Log2FC|>2 and P<0.05 were set to define differential genes, and the differential gene expression between untreated iPSCs and other groups was detected. There are 38, 27 and 5960 differential genes between iPSCs and iPSC / iOB, iPSC / iFC and Fibroblast, respectively ( Figure 3 B, 3C). Gene clustering results showed that iPSCs were more similar to iPSC / iFCs and iPSC / iOBs, but different from fibroblasts ( Figure 3 D). This is also consistent with the overall transcriptional profile results of gene expression ( Figure 3 E).
[0096] Subsequently, the present invention uses the purified iPSC / iOB and iPSC / iFC as the starting point to detect the EB formation ability of the two. Figure 4 As shown in A, as time goes by, EBs gradually form and their diameter gradually increases. After EBs are plated on a Matrigel-coated 6-well plate, cells migrate from the EB sphere to the bottom of the culture dish. qPCR results show that after EB sphere formation, the expression of stemness genes OCT4 and SOX2 in iPSC / iFC and iPSC / iOB is significantly reduced, while the expression of three germ layer differentiation markers SOX17, SOX17, Brachyury, DLX3, and PAX6 is significantly increased ( Figure 4 B). After immunofluorescence staining of the migrated cells, it was found that some of the migrated cells expressed ectoderm markers (βIII-Tublin, Nestin), mesoderm markers (αSMA, PDGFRa) and endoderm markers (GATA4) ( Figure 4 C). Thus, iPSC / iOB and iPSC / iFC have the ability to form EBs, which is consistent with iPSCs.
[0097] Subsequently, the present invention uses the purified iPSC / iOB and iPSC / iFC as the starting point to detect the three-germ layer differentiation ability of the two. Neuroectoderm, fibrochondrocytes, and endoderm are selected as the three-germ layer differentiation endpoints. The differentiated cells are as follows Figure 5 As shown in A. Immunofluorescence was used to detect the expression of specific markers of differentiated cells. The results showed that the neuroectodermal cells derived from iPSC / iOB and iPSC / iFC expressed the neuroectodermal markers Nestin, PAX6 and SOX2; the fibrochondrocytes derived from iPSC / iOB and iPSC / iFC expressed the fibrochondrocyte markers Col-I, Col-II, ACAN, SOX9; the mesendodermal cells derived from iPSC / iOB and iPSC / iFC expressed the endoderm marker GATA4 ( Figure 5 B). qPCR results showed that there was no significant difference in the expression levels of ectoderm, endoderm, mesoderm, and pluripotent stem cell markers between iPSCs, iPSC / iFC, and iPSC / iOB ( Figure 5 C). On the other hand, after directed differentiation of iPSC / iFC and iPSC / iOB into neuroectoderm, fibrochondrocytes and endoderm, the expression of ectoderm markers (DLX3 and PAX6), fibrochondrocyte markers (ACAN, SOX9, COL1A1) and endoderm marker (SOX17) increased significantly, accompanied by a decrease in the expression of pluripotent stem cell marker OCT4 ( Figure 5D). Therefore, iPSC / iOB and iPSC / iFC have the ability to differentiate into three germ layer cells in vitro, which is consistent with iPSCs.
Claims
1. Application of balanced salt solution without calcium ions and magnesium ions in purifying pluripotent stem cells.
2. The use according to claim 1, characterized in that: The balanced salt solution comprises DPBS, EBSS, HBSS, PBS, GBSS, RBSS, SBSS, TBS and / or TBSS; Optionally, the balanced salt solution is DPBS.
3. The use according to claim 1, characterized in that: The pluripotent stem cells include iPSC, ESC and / or EPSC; Optionally, the pluripotent stem cells are iPSCs.
4. A method for purifying pluripotent stem cells, characterized in that: The method comprises the following steps: treating a mixed cell system containing pluripotent stem cells in need with a balanced salt solution free of calcium ions and magnesium ions to purify the pluripotent stem cells.
5. The method according to claim 4, characterized in that The balanced salt solution comprises DPBS, EBSS, HBSS, PBS, GBSS, RBSS, SBSS, TBS and / or TBSS; Optionally, the balanced salt solution is DPBS; Optionally, the pluripotent stem cells include iPSCs, ESCs and / or EPSCs; Optionally, the pluripotent stem cells are iPSCs.
6. The method according to claim 4, characterized in that The mixed cell system also includes cells that are not pluripotent stem cells; Optionally, the non-pluripotent stem cell cells include cells derived from pluripotent stem cells; Optionally, the pluripotent stem cell-derived cells include pluripotent stem cell-derived MSCs, pluripotent stem cell-derived osteoblasts, pluripotent stem cell-derived fibrochondrocytes and / or pluripotent stem cell-derived EPCs.
7. The method according to claim 4, characterized in that The method comprises the following steps: (1) treating a mixed cell containing pluripotent stem cells in need with a balanced salt solution free of calcium ions and magnesium ions to obtain a supernatant solution; (2) After the supernatant solution is centrifuged, the supernatant is discarded to obtain purified pluripotent stem cells.
8. The method according to claim 7, characterized in that The treatment condition is 37°C for 30 min; Optionally, the amount of the balanced salt solution without calcium ions and magnesium ions is 0.5-3.5 mL per well of the cell culture plate; Optionally, the amount of the balanced salt solution without calcium ions and magnesium ions is 3 mL per well of the cell culture plate.
9. The application of any one of the following aspects, characterized in that: The applications include: (1) Use of a balanced salt solution free of calcium ions and magnesium ions in purifying pluripotent stem cells from abnormally differentiated pluripotent stem cells; (2) Use of a balanced salt solution free of calcium ions and magnesium ions for purifying pluripotent stem cells from pluripotent stem cells co-cultured with non-pluripotent stem cells; (3) Application of balanced salt solution without calcium ions and magnesium ions in the study of signal crosstalk between pluripotent stem cells and pluripotent stem cell-derived cells.
10. The use according to claim 9, characterized in that: The balanced salt solution comprises DPBS, EBSS, HBSS, PBS, GBSS, RBSS, SBSS, TBS and / or TBSS; Optionally, the balanced salt solution is DPBS; Optionally, the pluripotent stem cells include iPSCs, ESCs and / or EPSCs; Optionally, the pluripotent stem cells are iPSCs.
Citation Information
Patent Citations
Novel ips cell inducing method
CN109913494A
Rapid induced differentiation method of mesenchymal stem cells, kit and application of rapid induced differentiation method
CN115094031A
Preparation method, product and application of high-regeneration passage fibrochondrocyte
CN117126801A
Method for inducing pluripotent stem cells to be differentiated into osteoblasts and osteoblasts and application
CN117535234A
Cited By
Method for removing residual pluripotent stem cells after differentiation of pluripotent stem cells
CN118956720A
A method for eliminating residual pluripotent stem cells after pluripotent stem cell differentiation
CN118956720B
